Heron Therapeutics Statistics
Total Valuation
HRTX has a market cap or net worth of $59.08 million. The enterprise value is $167.36 million.
| Market Cap | 59.08M |
| Enterprise Value | 167.36M |
Important Dates
The last earnings date was Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HRTX has 190.27 million shares outstanding. The number of shares has increased by 20.17% in one year.
| Current Share Class | 190.27M |
| Shares Outstanding | 190.27M |
| Shares Change (YoY) | +20.17% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 1.07% |
| Owned by Institutions (%) | 46.07% |
| Float | 146.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.40 |
| Forward PS | 1.74 |
| PB Ratio | 15.25 |
| P/TBV Ratio | 15.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.33, with a Debt / Equity ratio of 26.80.
| Current Ratio | 2.33 |
| Quick Ratio | 1.23 |
| Debt / Equity | 26.80 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.57 |
Financial Efficiency
Return on equity (ROE) is -217.77% and return on invested capital (ROIC) is -3.61%.
| Return on Equity (ROE) | -217.77% |
| Return on Assets (ROA) | -2.20% |
| Return on Invested Capital (ROIC) | -3.61% |
| Return on Capital Employed (ROCE) | -6.00% |
| Weighted Average Cost of Capital (WACC) | 10.29% |
| Revenue Per Employee | $1.16M |
| Profits Per Employee | -$168,438 |
| Employee Count | 128 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.67 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.03% in the last 52 weeks. The beta is 1.65, so HRTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.65 |
| 52-Week Price Change | -72.03% |
| 50-Day Moving Average | 0.33 |
| 200-Day Moving Average | 0.65 |
| Relative Strength Index (RSI) | 46.86 |
| Average Volume (20 Days) | 9,421,797 |
Short Selling Information
The latest short interest is 34.00 million, so 17.87% of the outstanding shares have been sold short.
| Short Interest | 34.00M |
| Short Previous Month | 36.74M |
| Short % of Shares Out | 17.87% |
| Short % of Float | 23.16% |
| Short Ratio (days to cover) | 15.45 |
Income Statement
In the last 12 months, HRTX had revenue of $148.22 million and -$21.56 million in losses. Loss per share was -$0.11.
| Revenue | 148.22M |
| Gross Profit | 94.00M |
| Operating Income | -8.44M |
| Pretax Income | -21.56M |
| Net Income | -21.56M |
| EBITDA | -6.53M |
| EBIT | -8.44M |
| Loss Per Share | -$0.11 |
Balance Sheet
The company has $23.45 million in cash and $131.73 million in debt, with a net cash position of -$108.28 million or -$0.57 per share.
| Cash & Cash Equivalents | 23.45M |
| Total Debt | 131.73M |
| Net Cash | -108.28M |
| Net Cash Per Share | -$0.57 |
| Equity (Book Value) | 4.92M |
| Book Value Per Share | 0.02 |
| Working Capital | 119.26M |
Cash Flow
In the last 12 months, operating cash flow was -$13.73 million and capital expenditures -$631,000, giving a free cash flow of -$14.36 million.
| Operating Cash Flow | -13.73M |
| Capital Expenditures | -631,000 |
| Depreciation & Amortization | 1.91M |
| Net Borrowing | -23.15M |
| Free Cash Flow | -14.36M |
| FCF Per Share | -$0.08 |
Margins
Gross margin is 63.42%, with operating and profit margins of -5.69% and -14.55%.
| Gross Margin | 63.42% |
| Operating Margin | -5.69% |
| Pretax Margin | -14.55% |
| Profit Margin | -14.55% |
| EBITDA Margin | -4.41% |
| EBIT Margin | -5.69% |
| FCF Margin | n/a |
Dividends & Yields
HRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -20.17% |
| Shareholder Yield | -20.17% |
| Earnings Yield | -36.79% |
| FCF Yield | -24.31% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 0.15% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on January 13, 2014. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 13, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
HRTX has an Altman Z-Score of -10.31 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.31 |
| Piotroski F-Score | 2 |